EU–US pharmaceutical tariffs and 'most-favoured-nation' pricing: what it does to European prices and launches

What changed

Tariffs. The EU–US Joint Statement of 21 August 2025 capped US tariffs on EU goods, pharmaceuticals included, at an all-inclusive 15%, and committed the United States to most-favoured-nation (that is, ordinary) duty on EU generics, active ingredients and precursors from 1 September 2025. The EU’s side of the bargain, lower tariffs on US industrial goods, was adopted by the Council on 25 June 2026 and entered into force on 1 July 2026, with a sunset in 2029.

On 2 April 2026 the US President issued a Section 232 proclamation on pharmaceutical imports: a 100% tariff on patented pharmaceuticals and their ingredients, reduced to 15% for the EU, Japan, Korea and Switzerland under their trade frameworks, 0% for the United Kingdom under its December 2025 arrangement, with exemptions for companies that have agreed US investment or pricing deals. It was phased in on 31 July and 29 September 2026. Generics and their ingredients are exempt “at this time”, with a Commerce Department review within a year.

Most-favoured-nation pricing. The US executive order of May 2025 told companies to charge US patients no more than the lowest price in comparable rich countries. Rather than regulate, the administration has signed deals: Pfizer on 30 September 2025, nine more companies on 19 December 2025, nine more on 31 August 2026, twenty-six in all, including the largest generics companies. The deals commit the companies to most-favoured-nation prices on new US launches and to “rebalance international pricing”, which in plain terms means raising prices, or delaying launches, outside the United States so that the US price is no longer the highest.

The European reaction. Trade reporting puts EU launches of new medicines down about a third in the ten months after the order. Parliament’s health committee tabled questions in October 2026 urging pooled EU purchasing, and the Commission has framed the pharmaceutical package, the Critical Medicines Act and the Biotech Act as Europe’s answer.

What it means if you are…

A parallel trader. The differentials parallel trade works on are between European countries, and the MFN deals push companies to lift the low ones. Where a company raises its launch price in a low-price Member State, or does not launch there at all, the gap between that country and Germany or the UK narrows. Expect fewer very cheap source markets for new products, and expect launch sequencing designed to keep the lowest public price out of the US reference basket.

A generics or launch planner. The generics tariff exemption is the live question: it holds “at this time” and is under review. For a European generics exporter to the United States that is a one-year planning horizon. In Europe the effect is on the originators’ side: later EU launches of new products mean later loss-of-exclusivity dates for the generics that follow them, because the regulatory clocks start at authorisation, not launch.

A buyer. Higher European list and net prices for new originators, and delayed launches, are the designed outcome of “rebalancing”. The UK has already agreed to a 25% rise in net prices for new medicines as part of its own arrangement, covered separately.

What to watch

The Commerce review of the generics exemption, due by spring 2027; whether the Commission moves on joint purchasing; the EU’s 2029 sunset on the trade framework; and the first evidence from the national price lists of launch prices in the low-price Member States moving up.